Friday, October 13, 2017 9:31:06 AM
By Rachel Graf
Law360, New York (October 12, 2017, 1:56 PM EDT) -- Three pharmaceutical companies involved in a $1 billion patent infringement suit over a quality control test for a generic blood thinner contested each other’s dueling bids for post-trial relief Wednesday — including judgment or a new trial — after a jury found the patent was infringed but the claims were nonetheless invalid.
Momenta Pharmaceuticals and Sandoz Inc., which alleged the patent infringement, argued that Amphastar Pharmaceuticals' request for a ruling that it hadn’t infringed U.S. Patent Number 7,575,886 does not reflect the evidence that was presented at...
Needs subscription -
https://www.law360.com/trials/articles/973666/trio-of-pharma-cos-fight-post-trial-bids-in-1b-patent-row
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM